Stock Analysis on Net
Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying users area

Try for free

Abiomed Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Abiomed Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Accounts payable
Employee compensation
Research and development
Marketing
Warranty
Sales and income taxes
Professional, legal and accounting fees
Other
Accrued expenses
Deferred revenue
Other current liabilities
Current portion of capital lease obligation
Current liabilities
Other long-term liabilities
Contingent consideration
Deferred tax liabilities
Capital lease obligation, net of current portion
Long-term liabilities
Total liabilities
Class B Preferred Stock, $.01 par value; none issued and outstanding
Common stock, $.01 par value
Additional paid in capital
Retained earnings (accumulated deficit)
Treasury stock at cost
Accumulated other comprehensive loss
Stockholders’ equity
Total liabilities and stockholders’ equity

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Abiomed Inc. current liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2020 to 2021 and from 2021 to 2022.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Abiomed Inc. long-term liabilities as a percentage of total liabilities and stockholders’ equity increased from 2020 to 2021 but then slightly decreased from 2021 to 2022 not reaching 2020 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Abiomed Inc. total liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2020 to 2021 and from 2021 to 2022.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Abiomed Inc. stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from 2020 to 2021 and from 2021 to 2022.